Cambiar Investors LLC Cuts Holdings in Maximus, Inc. (NYSE:MMS)

Cambiar Investors LLC decreased its position in shares of Maximus, Inc. (NYSE:MMS) by 13.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 114,120 shares of the health services provider’s stock after selling 17,850 shares during the period. Cambiar Investors LLC owned approximately 0.19% of Maximus worth $8,519,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in MMS. V Square Quantitative Management LLC purchased a new position in shares of Maximus during the third quarter valued at about $25,000. UMB Bank n.a. grew its position in Maximus by 79.8% in the fourth quarter. UMB Bank n.a. now owns 356 shares of the health services provider’s stock worth $27,000 after acquiring an additional 158 shares in the last quarter. Eastern Bank purchased a new position in Maximus in the fourth quarter worth about $29,000. R Squared Ltd purchased a new position in Maximus in the fourth quarter worth about $54,000. Finally, GAMMA Investing LLC grew its position in Maximus by 150.6% in the third quarter. GAMMA Investing LLC now owns 862 shares of the health services provider’s stock worth $80,000 after acquiring an additional 518 shares in the last quarter. Hedge funds and other institutional investors own 97.21% of the company’s stock.

Maximus Stock Down 0.1 %

Shares of NYSE:MMS opened at $69.75 on Tuesday. Maximus, Inc. has a 1 year low of $68.15 and a 1 year high of $93.97. The business has a 50 day simple moving average of $74.64 and a two-hundred day simple moving average of $83.12. The firm has a market capitalization of $3.98 billion, a PE ratio of 15.00 and a beta of 0.72. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.72 and a quick ratio of 1.49.

Maximus (NYSE:MMS) last announced its earnings results on Thursday, February 6th. The health services provider reported $1.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.22. Maximus had a return on equity of 21.95% and a net margin of 5.28%. On average, equities analysts predict that Maximus, Inc. will post 6.05 EPS for the current year.

Maximus Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 28th. Shareholders of record on Saturday, February 15th will be given a dividend of $0.30 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $1.20 annualized dividend and a dividend yield of 1.72%. Maximus’s dividend payout ratio (DPR) is presently 25.81%.

Insider Buying and Selling at Maximus

In other news, insider Michelle F. Link sold 2,208 shares of Maximus stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $73.83, for a total transaction of $163,016.64. Following the completion of the sale, the insider now owns 6,567 shares of the company’s stock, valued at approximately $484,841.61. The trade was a 25.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Bruce Caswell purchased 3,500 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The shares were bought at an average cost of $70.64 per share, with a total value of $247,240.00. Following the purchase, the chief executive officer now directly owns 275,929 shares of the company’s stock, valued at approximately $19,491,624.56. This represents a 1.28 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 7,063 shares of company stock worth $502,017 over the last 90 days. Company insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on MMS shares. Raymond James upgraded Maximus from a “market perform” rating to an “outperform” rating and set a $90.00 price target for the company in a research report on Thursday, January 2nd. StockNews.com upgraded Maximus from a “hold” rating to a “buy” rating in a research report on Thursday, February 6th.

About Maximus

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.